Convergent Tx

Convergent Therapeutics develops targeted alpha therapies, including actinium-based agents against PSMA for prostate cancer and other solid tumors.
Domain
Healthcare
Status
Current Private Investment
Stage of Initial Investment
Series A
Initial Investment Year
2023
Convergent Portco Hover Image